Market Research Logo

Diabetic Neuropathy Treatment: World Market 2018-2028

Diabetic Neuropathy Treatment: World Market 2018-2028

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 215page report you will receive 85 tables and 90 figures– all unavailable elsewhere.

The 215page report provides clear detailed insight into the Global Diabetic Neuropathy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Diabetic Neuropathy Market forecasts from 20182028
  • This report breaks down the revenue forecast of the Global Diabetic Neuropathy market into these leading segments:
  • By Disorder:
  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy
  • By Treatment:
  • Drugs
  • AntiDepressants
  • AntiConvulsant
  • Radiotherapy
  • Physiotherapy
  • By End User:
  • Hospitals
  • Clinics
  • Pharmacy
Each submarket is further divided by region: North America, South America, Europe, AsiaPacific and RoW
  • This report provides individual revenue forecasts to 2028 for these regional and national markets:
  • North America: the US, Canada, Mexico
  • South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America
  • Europe: Germany, France, the UK, Spain, Italy, Russia, Rest of Europe
  • AsiaPacific: China, Japan, India, Australia, Thailand, Rest of AsiaPacific
  • Rest of the World: Middle East, Africa, Other Countries
  • Our study provides a SWOT analysis and Porter’s Five Forces analysis of the Global Diabetic Neuropathy market
  • This report discusses the leading companies in the Global Diabetic Neuropathy market
  • Abbott Laboratories
  • F. HoffmannLa Roche Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson
  • GlaxoSmithKline plc.
  • Lupin Limited
  • Glenmark Pharmaceuticals Limited
  • Depomed, Inc.
  • Astellas Pharma Inc.
  • Pfizer Inc.
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Diabetic Neuropathy Market. You find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (nonprintable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Global Diabetic Neuropathy Treatment Market Overview
1.2 Research Methodology
1.2.1 Primary Research
1.2.2 Secondary Research
1.2.3 Market Evaluation & Forecasting Methodology
1.3 Global Diabetic Neuropathy Treatment Market Segmentation
1.4 Overview of Findings
1.5 Why You Should Read This Report
1.6 How this report delivers?
1.7 Key Questions Answered by This Analytical Report
1.8 Frequently Asked Questions (FAQ)
1.9 Who is This Report For?
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Diabetic Neuropathy Treatment Market
3. Global Diabetic Neuropathy Treatment Market Forecast to 2028
4. Global Diabetic Neuropathy Treatment Market, by Disorder: Market Forecast to 2028
4.1 Overview
4.2 Peripheral Neuropathy
4.3 Autonomic Neuropathy
4.4 Proximal Neuropathy
4.5 Focal Neuropathy
5. Global Diabetic Neuropathy Treatment Market by Treatment: Market Forecast to 2028
5.1 Overview
5.2 Drugs
5.3 Anti-depressants
5.4 Anti-convulsant
5.5 Radiotherapy
5.6 Physiotherapy
5.7 Others
6. Global Diabetic Neuropathy Treatment Market by End-User: Market Forecast to 2028
6.1 Overview
6.2 Hospitals
6.3 Clinics
6.4 Pharmacy
7. Regional Diabetic Neuropathy Treatment Market Forecasts to 2027
7.1 Regional Diabetic Neuropathy Treatment Market Forecast Overview
7.2 North American Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.2.1 USA Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.2.2 Canada Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.2.3 Mexico Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.3 South American Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.3.1 Brazil Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.3.2 Argentina Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.3.3 Paraguay Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.3.4 Bolivia Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.3.5 Rest of South America Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4 European Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.1 France Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.2 Germany Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.3 UK Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.4 Spain Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.5 Italy Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.6 Russia Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.7 Rest of Europe Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5 Asia-Pacific Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5.1 China Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5.2 Japan Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5.3 India Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5.4 Australia Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5.5 Thailand Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5.6 Rest of Asia-Pacific Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.6 Rest of World Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.6.1 Middle East Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.6.2 Africa Cancer Diabetic Neuropathy Treatment Forecast 2017-2028
7.6.3 Other Countries Diabetic Neuropathy Treatment Market Forecast 2017-2028
8. Diabetic Neuropathy Treatment Market, Qualitative Analysis, 2017-2028
8.1 Porter’s Five Forces Analysis of the Diabetic Neuropathy Treatment Market 2017-2028
8.1.1 Bargaining Power of Buyers (Medium)
8.1.2 Bargaining Power of Suppliers (Low)
8.1.3 Threat of New Entrants (Low)
8.1.4 Threat of Substitute Products (Low)
8.1.5 Intensity of Competitive Rivalry (High)
8.2 Drivers, Restrains & Opportunities
8.2.1 Drivers
8.2.1.1 Increasing Incidences Of Diabetes
8.2.1.2 Increasing Aging Population
8.2.2 Restraints
8.2.2.1 Stringent Government Regulation
8.2.3 Opportunities
8.2.3.1 Ongoing Research And Development Related To Diabetes Neuropathy
9. Leading Companies in Diabetic Neuropathy Treatment Market
9.1 GlaxoSmithKline PLC
9.1.1 GlaxoSmithKline PLC: Company Overview
9.1.2 GlaxoSmithKline PLC: Product Portfolio
9.2 F. Hoffmann-La Roche AG
9.2.1 F. Hoffmann-La Roche: Company Overview
9.2.2 F. Hoffmann-La Roche: Product Portfolio
9.2.3 F. Hoffmann-La Roche: Recent Developments
9.3 Pfizer Inc.
9.3.1 Pfizer Inc.: Company Overview
9.3.2 Pfizer Inc.: Product Portfolio
9.4 Abbott Diagnostics (A Business Division of Abbott Laboratories Inc.)
9.4.1 Abbott Diagnostics: Company Overview
9.4.2 Abbott Diagnostics: Product Portfolio
9.5 Johnson & Johnson
9.5.1 Johnson & Johnson: Company Overview
9.5.2 Johnson & Johnson: Product Portfolio
9.5.3 Johnson & Johnson: Recent Developments
9.6 Eli Lilly and Company
9.6.1 Eli Lilly and Company: Company Overview
9.6.2 Eli Lilly and Company: Product Portfolio
9.7 Astellas Pharma, Inc.
9.7.1 Astellas Pharma, Inc.: Company Overview
9.7.2 Astellas Pharma, Inc.: Recent Development
9.8 Glenmark Pharmaceuticals Ltd.
9.8.1 Glenmark Pharmaceuticals Ltd.: Company Overview
9.8.2 Glenmark Pharmaceuticals Ltd.: Product Portfolio
9.9 Depomed, Inc.
9.9.1 Depomed, Inc. : Company Overview
9.9.2 Depomed, Inc.: Recent Development
9.10 Lupin Ltd.
9.10.1 Lupin Ltd.: Company Overview
9.10.2 Lupin Ltd.: Product Portfolio
9.11 Other Companies Involved in Diabetic Neuropathy Treatment Market
10. Conclusions
10.1 Current Leading Segments
10.2 Leading Regional Markets
10.3 Emerging Markets
10.4 The Future of the Market?
11. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
List of Figures
Figure 1.1. Diabetic Neuropathy Treatment Market Segmentation
Figure 3.1 Diabetic Neuropathy Treatment, by Disorder, ($bn), 2017-2028
Figure 3.2 Global Diabetic Neuropathy Treatment Market, by Treatment, ($bn), 2017-2028
Figure 3.3 Global Diabetic Neuropathy Treatment Market, by End-User, ($bn), 2017-2028
Figure 4.1 Global Diabetic Neuropathy Treatment Market Forecast, by Disorder ($bn) 2017-2028
Figure 4.2 Diabetic Neuropathy Treatment Market, by Disorder, Market Share (%), 2017
Figure 4.3 Global Diabetic Neuropathy Treatment Market Forecast for Peripheral Neuropathy, by Geography, ($bn) 2017-2028
Figure 4.4 Global Diabetic Neuropathy Treatment Market Forecast for Autonomic Neuropathy, by Geography, ($bn) 2017-2028
Figure 4.5 Global Diabetic Neuropathy Treatment Market Forecast for Proximal Neuropathy, by Geography, ($bn) 2017-2028
Figure 4.6 Global Diabetic Neuropathy Treatment Market Forecast for Focal Neuropathy, by Geography, ($bn) 2017-2028
Figure 5.1 Global Neuropathy Treatment Market Forecast for Treatment, by Treatment ($bn) 2017-2028
Figure 5.2 Global Diabetic Neuropathy Treatment Market, by Treatment, Market Share (%), 2017
Figure 5.3 Global Diabetic Neuropathy Treatment Market for Drugs Forecast, by Geography($bn) 2017-2028
Figure 5.4 Global Diabetic Neuropathy Treatment Market for Anti-depressants Forecast, by Geography($bn) 2017-2028
Figure 5.5 Global Diabetic Neuropathy Treatment Market for Anti-convulsant Forecast, by Geography($bn) 2017-2028
Figure 5.6 Global Diabetic Neuropathy Treatment Market for Radiotherapy Forecast, by Geography($bn) 2017-2028
Figure 5.7 Global Diabetic Neuropathy Treatment Market for Physiotherapy Forecast, by Geography($bn) 2017-2028
Figure 5.8 Global Diabetic Neuropathy Treatment Market for Other Immunotherapeutic Agents Forecast, by Geography($bn) 2017-2028
Figure 6.1 Global Neuropathy Treatment Market Forecast for Treatment, by End-User ($bn) 2017-2028
Figure 6.2 Global Diabetic Neuropathy Treatment Market, by End-User, Market Share (%), 2017
Figure 6.3 Global Diabetic Neuropathy Treatment Market for Hospitals Forecast, by Geography($bn) 2017-2028
Figure 6.4 Global Diabetic Neuropathy Treatment Market for Clinics Forecast, by Geography ($bn) 2017-2028
Figure 6.5 Global Diabetic Neuropathy Treatment Market for Pharmacy Forecast, by Geography($bn) 2017-2028
Figure 7.1 Global Diabetic Neuropathy Treatment Market Forecast, by Geography, by Geography($bn) 2017-2028
Figure 7.2 Global Diabetic Neuropathy Treatment Market Forecast, by Geography, Market Share (%), 2017
Figure 7.3 North America Diabetic Neuropathy Treatment Market Forecast, by Country($bn) 2017-2028
Figure 7.4 North America Diabetic Neuropathy Treatment Market, by Country, Market Share (%), 2017
Figure 7.5 USA Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.6 Canada Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.7 Mexico Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.8 South America Diabetic Neuropathy Treatment Market Forecast, by Country($bn) 2017-2028
Figure 7.9 South America Diabetic Neuropathy Treatment Market, by Country, Market Share (%), 2017
Figure 7.10 Brazil Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.11 Argentina Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.12 Paraguay Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.13 Bolivia Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.14 Rest of South America Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.15 Europe Diabetic Neuropathy Treatment Market Forecast, by Country($bn) 2017-2028
Figure 7.16 Europe Diabetic Neuropathy Treatment Market, by Country, Market Share (%), 2017
Figure 7.17 France Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.18 Germany Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.19 UK Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.20 Spain Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.21 Italy Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.22 Russia Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.23 Rest of Europe Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.24 Asia-Pacific Diabetic Neuropathy Treatment Market Forecast, by Country ($bn) 2017-2028
Figure 7.25 Asia-Pacific Diabetic Neuropathy Treatment Market, Market Share (%), 2017
Figure 7.26 China Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.27 Japan Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.28 India Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.29 Australia Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.30 Thailand Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.31 Rest of Asia-Pacific Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.32 RoW Diabetic Neuropathy Treatment Market Forecast, by Country($bn) 2017-2028
Figure 7.33 Rest of World Diabetic Neuropathy Treatment Market, by Country, Market Share (%), 2017
Figure 7.34 Middle East Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.35 Africa Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.36 Other Countries Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 8.1 Porter’s Five Forces Analysis of the Diabetic Neuropathy Treatment Market
Figure 8.2 Estimated of person aged 60 years and over in year 2015, 2030 and 2050
Figure 9.1 GlaxoSmithKline PLC, Revenue, ($million), 2012-2016
Figure 9.2 GlaxoSmithKline PLC, Product Segments Share (%), 2016
Figure 9.3 GlaxoSmithKline PLC, Geographical Presence Share (%), 2016
Figure 9.4 F. Hoffmann-La Roche, Revenue, ($million), 2012-2016
Figure 9.5 F. Hoffmann-La Roche, Product Segments Share (%), 2016
Figure 9.6 F. Hoffmann-La Roche, Geographical Presence Share (%), 2016
Figure 9.7 Pfizer Inc., Revenue, ($million), 2012-2016
Figure 9.8 Pfizer Inc., Product Segments Share (%), 2016
Figure 9.9 Pfizer Inc., Geographical Presence Share (%), 2016
Figure 9.10 Abbott Diagnostics , Revenue, ($million), 2012-2016
Figure 9.11 Abbott Diagnostics (Segment) , Revenue, ($million), 2012-2016
Figure 9.12 Abbott Diagnostics, Product Segments Share (%), 2016
Figure 9.13 Abbott Diagnostics, Geographic Presence Share (%), 2016
Figure 9.14 Johnson & Johnson, Revenue, ($million), 2012-2016
Figure 9.15 Johnson & Johnson, Product Segments Share (%), 2016
Figure 9.16 Johnson & Johnson, Geographical Presence Share (%), 2016
Figure 9.17 Eli Lilly and Company, Revenue, ($million), 2012-2016
Figure 9.18 Eli Lilly and Company, Product Segments Share (%), 2016
Figure 9.19 Eli Lilly and Company, Geographical Presence Share (%), 2016
Figure 9.20 Astellas Pharma, Inc., Revenue, ($million), 2013-2017
Figure 9.21 Astellas Pharma, Inc., Geographical Presence Share (%), 2017
Figure 9.22 Glenmark Pharmaceuticals Ltd., Revenue, ($million), 2013-2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report